Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system-Reference-Cited by-同舟云学术

Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system

Published:2023-08-25 Issue: Volume: Page:1-8
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Li Chunlei¹^ORCID,Li Zhengjun²,Sun Qing²,Xiang Yanxiao¹,Liu Anchang¹³⁴

Affiliation:

1. Department of Pharmacy, Qilu Hospital of Shandong University, Jinan, China

2. Department of Dermatology, Qilu Hospital of Shandong University, Jinan, China

3. Department of Pharmacy, Qilu Hospital of Shandong University (Qingdao), Qingdao, China

4. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2251381

Reference46 articles.

1. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

2. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

3. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1

4. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

5. FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma;Cancers;2024-08-27